Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cemacabtagene ansegedleucel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| cemacabtagene ansegedleucel | EXPERIMENTAL | Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide. |
| Observation | OTHER | Participants do not receive any study treatments. They are observed as per the current standard of care. |
| Name | Type | Description |
|---|---|---|
| cemacabtagene ansegedleucel | GENETIC | An allogeneic CAR T cell therapy targeting CD19 |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
| Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ | DEVICE | A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL. |
Key Inclusion Criteria: 1. LBCL per WHO 2017 including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and primary mediastinal B-cell lymphoma histologically confirmed by pathology report. 2. Participant has completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjus...
Cemacabtagene ansegedleucel, also known as cema-cel, is an investigational gene therapy being studied for use in patients with Large B-cell Lymphoma (LBCL). It is currently in Phase 2 clinical development as a consolidation treatment for patients in first-line minimal residual disease (MRD) positive remission.
Cemacabtagene ansegedleucel is a cell therapy, classified under the -cel (cell therapy) target class. It is designed to target cancer cells in Large B-cell Lymphoma, though the specific molecular target is not disclosed in the available information.
Cemacabtagene ansegedleucel is being developed by Allogene Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALLO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Large B-cell Lymphoma.
Cemacabtagene ansegedleucel is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for treating Large B-cell Lymphoma.
Cemacabtagene ansegedleucel is being evaluated in a Phase 2 clinical trial registered as NCT06500273, titled "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL." The trial is currently recruiting participants and aims to enroll approximately 250 patients across the United States, Australia, Canada, and South Korea.
Yes, cemacabtagene ansegedleucel is also known as cema-cel. Both names refer to the same investigational cell therapy being developed by Allogene Therapeutics for the treatment of Large B-cell Lymphoma.